IL-12 Deficiency in MRL-Faslpr Mice Delays Nephritis and Intrarenal IFN-γ Expression, and Diminishes Systemic Pathology

Eriya Kikawada, Deborah M. Lenda and Vicki R. Kelley
J Immunol April 1, 2003, 170 (7) 3915-3925; DOI: https://doi.org/10.4049/jimmunol.170.7.3915

Abstract

Autoimmune disease in MRL-Faslpr mice is characterized by fatal nephritis, systemic pathology, and autoantibodies, mimicking human lupus. We previously reported that 1) intrarenal IL-12 elicits nephritis by fostering the accumulation of intrarenal IFN-γ-secreting T cells, and 2) MRL-Faslpr mice deficient in the IFN-γ receptor were spared from nephritis. Therefore, we hypothesized that eliminating IL-12 in MRL-Faslpr mice reduces IFN-γ-secreting cells and thereby prevents systemic pathology. For this purpose, we constructed an IL-12p40-deficient MRL-Faslpr(IL-12−/−) strain. We determined that glomerular and interstitial, but not perivascular, renal pathology were decreased in IL-12−/− mice vs the wild-type (WT) strain (5 mo of age). Similarly, systemic pathology (lung, lacrimal and salivary glands, skin, and lymphadenopathy) was diminished. The intrarenal accumulation of T cells (CD4+, CD8+, CD4−CD8−B220+) and macrophages was dramatically reduced in IL-12−/− MRL-Faslpr kidneys. We determined that there were fewer IFN-γ transcripts (>70%) in the IL-12−/− protected kidneys compared with the WT kidneys. Similarly, cells propagated from IL-12−/− MRL-Faslpr kidneys generated substantially less IFN-γ when stimulated with IL-12 and IL-18 compared with those from WT kidneys, and we detected fewer CD8 and B220 T cells producing IFN-γ in these IL-12−/− MRL-Faslpr kidneys. Of note, survival was modestly extended in the IL-12−/− MRL-Faslpr mice. While lung and lacrimal and salivary gland pathology remained reduced in moribund IL-12−/− MRL-Faslpr mice, renal pathology and IFN-γ expression were equivalent to those in the WT strain. Thus, we suggest that IL-12 is a therapeutic target for multiple tissues in lupus; however blocking IL-12 alone is not sufficient to confer enduring protection from lupus nephritis.

The MRL-Faslpr mouse has a systemic autoimmune disease mimicking human lupus, characterized by inflammation in multiple tissues, skin, glands, lungs, and joints; massive lymphadenopathy; and splenomegaly (1, 2, 3). Kidney disease in the MRL-Faslpr strain is fatal and is dependent on the infiltration of T cells regulated by cytokines. Multiple T cell populations accumulate in the MRL-Faslpr kidney with nephritis, including CD4, CD8, and B220-positive T cells that lack CD4 and CD8 determinants, termed double-negative (DN)3 T cells (4, 5, 6). Furthermore, we have established that in the absence of CD4 and/or CD8 and DN T cell populations, MRL-Faslpr mice are totally protected from kidney disease (7). Thus, the regulation of T cells in the kidney is critical in the pathogenesis of autoimmune disease.

Cytokines, including IL-12 and IFN-γ, promote autoimmune disease in the MRL-Faslpr strain (5). MRL-Faslpr mice lacking IFN-γR or IFN-γ are spared from kidney disease and have a prolonged life span (8, 9). Since T cells within the kidney are a rich source of IFN-γ, cytokines that induce the production of IFN-γ are potential therapeutic targets for lupus (5, 10, 11, 12).

IL-12 released within the kidney in MRL-Faslpr mice may provide the signal for T cells to destroy the kidney. This concept is based on the following: 1) IL-12 generated by APC regulates T cells (13, 14, 15); 2) IL-12 promotes T cell proliferation (16, 17); 3) IL-12 stimulates T cells to generate IFN-γ (18); and 4) IL-12 is a prerequisite for committing CD4 T cells into a T cell subset (Th1) that is associated with disease in MRL-Faslpr mice (19, 20, 21). Furthermore, we have determined that local and systemic provision of IL-12 via gene transfer promotes IFN-γ-dependent nephritis in MRL-Faslpr mice (5), and IL-12 recruits CD4, CD8, and DN T cells into the kidney, activates kidney-infiltrating T cells to produce IFN-γ, and promotes the expansion of CD4 T cells within MRL-Faslpr kidneys (5). In addition, glomerulonephritis in young MRL-Faslpr mice is accelerated by injection of IL-12 (22). Taken together, these data suggest that IL-12 is required for autoimmune kidney disease.

IL-12 is a heterodimeric structure consisting of two disulfide-bonded subunits, p40 and p35 (23, 24, 25). Both subunits are required for the biological activity of IL-12 (26, 27). The introduction of a null mutation into the IL-12p40 gene of normal (C57BL/6) mice results in these mice being unable to produce bioactive IL-12, yet does not compromise their development (28). The primary defect in the IL-12p40−/− mice is the reduced generation of IFN-γ (28). IFN-γ production in IL-12p40−/− mice is impaired, but not completely lacking, in response to endotoxin (28). Similarly, IL-12p40−/− mice generate a reduction, but not an elimination, of IFN-γ+ CD4+ T cells following exposure to nonlethal infections with intracellular pathogens or repeated immunization with a pathogen extract (29). Thus, IL-12 diminishes the generation of IFN-γ-producing cells in response to immunological stimuli.

Taken together, we hypothesize that blocking IL-12 reduces lupus nephritis, intrarenal IFN-γ-generating cells, and systemic pathology in MRL-Faslpr mice. In this study we determined that there is a delay in renal disease (pathology, proteinuria) and systemic pathology (skin, lungs, lacrimal and salivary glands, lymphadenopathy) in IL-12p40 genetic deficient MRL-Faslpr mice (IL-12−/− MRL-Faslpr) compared with the wild-type (WT) strain. We detected fewer macrophages and T cells (CD4, CD8, and DN) in the IL-12−/− MRL-Faslpr kidneys compared with those from the WT strain (5 mo of age). In the absence of intrarenal IL-12, we detected a reduction in intrarenal IFN-γ-generating B220 and CD8 T cells. Eliminating IL-12 extended survival and protected the lungs, skin, and lacrimal and salivary (submandibular) glands from progressive injury. However, deleting IL-12 did not confer enduring protection from renal disease. This suggests that sufficient IFN-γ-generating cells remained, resulting in fatal disease. Taken together, eliminating IL-12 delays tissue injury in MRL-Faslpr mice. We suggest that an optimal therapeutic strategy should block IL-12 along with perhaps other IFN-γ-generating molecules.

Materials and Methods

Mice

MRL/MpJ++ (MRL++), MRL/MpJ-Faslpr/Faslpr(MRL-Faslpr), C3H/Fej, and C57BL/6, IL-12p40−/− mice on a C57BL/6 background were purchased from The Jackson Laboratory (Bar Harbor, ME), and housed and bred in our pathogen-free animal facility.

Generating IL-12-deficient MRL-Faslprmice

We constructed an IL-12p40-deficient MRL-Faslpr strain (IL-12−/− MRL-Faslpr) using a backcross-intercross scheme. MRL-Faslpr mice were bred with IL-12−/− (C57BL/6) mice to yield heterozygous F1 offspring. We intercrossed F1 mice and screened the progeny by PCR amplification of tail genomic DNA for the Faslpr mutation and for IL-12 using specific primers. After five generations of backcross-intercross matings, this breeding scheme generated a colony of MRL-Faslpr mice homozygous and heterozygous for the disrupted IL-12p40 gene. We analyzed the B5 generation as we have previously established that there are sufficient MRL-Faslpr background genes even by the B3 generation to result in phenotypic changes characteristic of the MRL-Faslpr strain. Identification of the disrupted and nondisrupted IL-12p40 in experimental mice was determined by PCR using tail genomic DNA. The DNA was assessed by PCR using oligonucleotide primers that recognize either the normal IL-12p40 gene (sense, 5′-AGT GAA CCT CAC CTG TGA CAC G-3′; antisense, 5′-TTT TTA CTG TGG ATG GAT-3′) or the neo gene (sense, 5′-ATT GAA CAA GAT GGA TTG CAC-3′; antisense, 5′-TCT TCG TCC AGA TCA TCC T-3′). Gel analysis of the PCR products identified the IL-12p40 and neo gene fragments at 500 bp.

We validated the expression of IL-12p40 when mice were sacrificed by measuring IL-12p40 in the serum using the Duo Set ELISA for mouse IL-12p40 (R&D System, Minneapolis, MN) and by measuring IL-12p40 transcripts in the kidney using RT-PCR (28).

Urinary protein

Urinary protein levels in IL-12−/− MRL-Faslpr and IL-12+/+ MRL-Faslpr mice were assessed semiquantitatively by dipstick analysis (Albustick; Bayer, Elkhart, IN) on a monthly basis beginning at 2 mo of age. On the day of analysis, dipstick proteinuria measurements were made in individual mice in the morning and repeated in the evening. If the measurements were inconsistent, the mouse was reassessed on the following day. The urinary protein (milligrams per deciliter)/creatinine (milligrams per deciliter) ratio was assessed in urine specimens as a more accurate measurement for proteinuria. Urine was collected from individual mice housed in metabolic cages for 24 h. The protein/creatinine ratio was measured at Children’s Hospital (Boston, MA).

Survival

Survival was assessed in the IL-12−/− and IL-12+/+ MRL-Faslpr strains and included moribund mice.

Gross pathology

Lymphadenopathy.

Lymphadenopathy (cervical, brachial, and inguinal) was assessed monthly beginning at 3 mo of age. We palpated the lymph node and scored them using a grade of 0–3 (0 = none; 1 = small, at one site; 2 = moderate, at two sites; 3 = large, at three or more different sites).

Skin lesions.

Skin lesions were assessed monthly beginning at 3 mo of age. We scored the skin lesions by gross pathology using a grade of 0–3 (0 = none; 1 = mild (snout and ears); 2 = moderate, <2 cm (snout, ears, and intrascapular); and 3 = severe, >2 cm (snout, ears, and intrascapular)).

Splenomegaly.

Spleen enlargement was assessed at the time of sacrifice or death. We compared spleen weights in IL-12+/+ and IL-12−/− MRL-Faslpr mice.

Histopathology

Renal.

The kidneys were fixed in 10% formalin for 3 h at 4°C. Paraffin sections (4 μm) were stained with H&E and the periodic acid-Schiff reagent. We evaluated glomerular pathology by assessing 20 glomerular cross-sections (gcs) per kidney and scored each glomerulus on a semiquantitative scale: 0 = normal (35–40 cells/gcs); 1 = mild (glomeruli with few lesions, with slight proliferative changes, and mild hypercellularity (41–50 cells/gcs), and/or minor exudation); 2 = moderate (glomeruli with moderate hypercellularity (50–60 cells/gcs), including segmental and/or diffuse proliferative changes, hyalinosis, and/or moderate exudates); and 3 = severe (glomeruli with segmental, or global sclerosis, and/or exhibiting severe hypercellularity (>60 cells/gcs), necrosis, crescent formation, and/or heavy exudation). Damaged tubules (percentage; consisting of dilation and/or atrophy and/or necrosis) were determined in 200 randomly selected renal cortical tubules per kidney (magnification, ×400). Perivascular cell accumulation was determined semiquantitatively by scoring the number of cell layers surrounding the majority of vessel walls on a 0–3 scale (0 = none; 1 = <5 cell layers; 2 = 5–10 cell layers; 3 = >10 cell layers). We evaluated renal pathology using coded slides.

Other tissues.

The lungs, lacrimal glands, and salivary glands were fixed in 10% formalin for 3 h at 4°C. Paraffin sections (4 μm) were stained with H&E and evaluated by light microscopy. The perivascular leukocyte infiltrations in the lungs were analyzed by morphomeric analysis. We measured the leukocyte infiltrates surrounding 10 random vessels (0 = none; 1 = <3 layers in <50%; 2 = 3–6 cell layers >50%; 3 = >6 layers). Peribronchiolar leukocyte infiltration was determined by semiquantitatively scoring the number of cells surrounding 10 random bronchi (0 = none; 1 = <3 layers >50% bronchi; 2 = 3–6 layers >50% bronchi; 3 = >6 layers >50% bronchi). We scored lacrimal gland pathology on a scale of 0–3 (grade 0 = no inflammatory cells; grade 1 = the presence of at least one focus; grade 2 = multiple foci; grade 3 = multiple foci plus evidence of gland destruction). We scored salivary gland inflammation on a scale of 0–3 (grade 0 = no inflammatory cells; grade 1 = few perivascular and periductal inflammatory infiltrates (<100 cells); grade 2 = moderate number of perivascular and periductal inflammatory infiltrates (=100–500 cells); grade 3 = extensive inflammation with large inflammatory foci (>500 cells)).

Immunohistochemistry

Cryostat-sectioned kidneys were stained for macrophages with CD68 (Serotec, Oxford, U.K.), and T cells were stained with anti-CD4, anti-CD8, and anti-B220 rat-anti-mouse mAb (BD PharMingen, San Diego, CA) according to a previously described immunoperoxidase method (30). The immunostaining was analyzed by counting for the presence of CD68, CD4, CD8, and B220-positive cells in 10 randomly selected high power fields. We determined that B220-positive cells in the kidney are unique DN T cells and are not B cells (5, 8, 31).

IgG and C3 deposits within renal glomeruli

Kidney cryostat cross-sections (4 μm thick) were stained with FITC-conjugated goat anti-mouse IgG and FITC-conjugated goat IgG fraction of mouse C3 (Cappel, Malvern, PA) for 30 min at 37°C. The fluorescence intensity within the peripheral glomerular capillary walls and the mesangium were scored on a scale of 0–3 (0 = none; 1 = weak; 2 = moderate; 3 = strong). At least 10 glomeruli/section were analyzed.

Identifying cytokine transcripts in the kidney and lymph nodes (PCR)

The expressions of IFN-γ, IL-18, CSF-1, GM-CSF, IL-4, and TNF-α in the renal cortex and of IFN-γ, GM-CSF, TNF-α, and IL-4 in the mesenteric lymph nodes were analyzed using real-time, two-step, quantitative RT-PCR. Total RNA was isolated from snap-frozen kidney cortexes and lymph nodes using TRIzol (Life Technologies, Gaithersburg, MD). Residual DNA was removed by treatment with 1 U of DNase I (Invitrogen, Carlsbad, CA) at room temperature for 15 min, followed by inactivation at 65°C for 10 min. The RT reaction was performed on 1 mg of RNA using an oligo(dT) primer and Superscript II reverse transcriptase (Life Technologies). Relative quantitation with real-time two-step RT-PCR was performed with SYBR Green PCR reagents (Qiagen, Valencia, CA) and an ABI PRISM 7700 sequence detection system (PE Applied Biosystems, Foster City, CA) according to the manufacturer’s instructions. Reactions were performed using 1.0 μl of cDNA at a concentration of 100 ng/ml in a reaction volume of 25 μl. The PCR consists of HotStar Taq activation for 15 min at 95°C, then 40 cycles with heating to 95°C for 15 s and cooling to 60°C for 1 min. The mRNA levels were normalized to those of GAPDH. The PCR primers used were as follows: GAPDH: sense, 5′-CAT GGC CTC CAA GGA GTA AG-3′; antisense, 5′-CCT AGG CCC CTC CTG TTA TT-3′; IL-18: sense, 5′-AGT GAA CCC CGA ACC AGA CT-3′; antisense, 5′-TTC AGG TGG ATC CAT TTC CT-3; IFN-γ: sense, 5′-AAC GCT ACA CAC TGC ATC TTG G-3′; antisense, 5′-GCC GTG GCA GTA ACA GCC-3′; CSF-1: sense, 5′-ACC TGG CAA GGG ACT CAC TA-3′; antisense, 5′-CAG GCT CTC TTC TTG GGA AA-3′; GM-CSF: sense, 5′-GGC AAT TTC ACC AAA CTC AA-3′; antisense, 5′-TGA AAT CG CAT AGG TGG TA-3; IL-4: sense, 5′-TCA TCG GCA TTT TGA ACG AG-3′; antisense, 5′-CGT TTG GCA CAT CCA TCT CC-3; and TNF-α: sense, 5′-TCA GCC GAT TTG CTA TCT CA-3′; antisense, 5′-TGG AAG ACT CCT CCC AGG TA-3.

Intrarenal IFN-γ protein (ELISA)

At the time of sacrifice, kidneys were removed and gently dissociated into single-cell suspensions. Red blood cells were removed by treatment with ACK lysing buffer (BioSource International, Camarillo, CA). Cell suspensions were resuspended in complete medium (RPMI 1640 medium supplemented with 10% FBS, 50 μM 2-ME, 50 μg/ml penicillin/streptomycin, and 2 mM l-glutamine; Cellgro, Herndon, VA).

To stimulate IFN-γ production, cell suspensions were cultured with recombinant murine IL-12 (10 μg/ml; PeproTech, Rocky Hill, NJ) and IL-18 (100 μg/ml; Endogen, Woburn, MA) for 48 h. IFN-γ in the supernatant was evaluated by ELISA according to published methods (18). Briefly, Maxisorp (Nunc, Naperville, IL) were coated with purified rat anti-mouse (clone R46A2; 1–5 μg/ml, 4°C overnight). After washing the plates, standards and samples (diluted 1/5) were added and incubated (4°C overnight). Wells were washed, and IFN-γ levels were determined by biotinylated rat anti-mouse IFN-γ Ab (clone XMG1.2) and a peroxidase visualization system. The Abs and reagents in these assays were purchased from BD PharMingen with the exception of avidin-peroxidase (Sigma-Aldrich, St. Louis, MO).

Identifying IFN-γ-expressing cells in the kidney (flow cytometry)

We removed the kidneys and gently homogenized them, lysed RBC with ACK lysing buffer (BioSource International), and washed the remaining cells in PBS. These cells were cultured in RPMI containing PMA (1 ng/ml; Sigma-Aldrich) and ionomycin (500 ng/ml; Sigma-Aldrich) for 4 h. Monensin (3 μM; Sigma-Aldrich) was added during the last 3 h. We washed the cells in PBS, suspended them in FACS buffer (PBS, 5% FBS, and 0.09% NaN3), and incubated them with several cell surface markers including FITC-conjugated anti-CD4 Ab (eBioscience, San Diego, CA), anti-CD8 Ab (eBioscience), or anti-CD45R/B220 Ab (eBioscience) for 30 min on ice. We permeabilized the cells, stained them with PE-labeled anti-IFN-γ Ab (eBioscience) for 30 min, washed them twice in saponin buffer, and suspended them in FACS buffer to allow the resealing of permeabilized membrane. Intracellular markers, FITC-anti-CD68 Ab (Serotec) and tubular epithelial cell (TEC) marker N-terminal KCC4 specific Ab (provided by Dr. D. Mount, Brigham and Women’s Hospital) were stained after the cells were permeabilized with saponin, followed by staining for the presence of IFN-γ as described above. We analyzed 50,000 cells by flow cytometry using a FACSCalibur.

Serum Ig profile

We measured total IgG and IgM, and IgG1, IgG2a, IgG2b and IgG3 isotypes by ELISA. Plates were coated overnight at 4°C with goat anti-mouse Ig capture Abs (Southern Biotechnology Associates, Birmingham, AL) in PBS. The wells were blocked for 2 h with 3% BSA/PBS. We added Ig standards to the plate using a series of 3-fold dilutions, and assessed serum samples using serial dilutions starting at 1/100. Standards and serum samples were incubated overnight at 4°C, and bound Ig was detected with goat anti-mouse detection Abs conjugated with HRP (Southern Biotechnology Associates) and 3,3′,5,5′-tetramethylbenzidine peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD). The absorbance was measured at 450 nm.

In addition, we measured the anti-dsDNA Ab isotypes (IgG1, IgG2a, IgG2b, IgG3) in the IL-12−/− and IL-12+/+ MRL-Faslpr mice at five dilutions (1/50 through 1/12,150) as previously reported (32).

Statistical analysis

The data represent the mean ± SEM. We determined statistical significance using ANOVA and/or Student’s t test. We compared the survival curves using the log-rank two-tailed test.

Results

Glomerular and tubular, but not perivascular, pathology is decreased in IL-12−/− MRL-Faslprkidneys

To evaluate renal pathology we sacrificed groups (n = 5) of IL-12−/− MRL-Faslpr and IL-12+/+ MRL-Faslpr mice at 5 mo of age. The glomerular pathology in IL-12−/− MRL-Faslpr mice was reduced compared with that in age- and sex-matched WT mice (p ≤ 0.001; Fig. 1⇓, a and d, arrowheads). In particular, there was a reduction in glomerular hypercellularity, glomerulosclerosis, and crescent formation. However, glomerular pathology was not entirely prevented; there was an increase in glomerular pathology in the IL-12−/− MRL-Faslpr mice compared with the age- and sex-matched mice with normal kidneys (MRL++, C3H/Fej; p ≤ 0.001). Similarly, there was less tubular pathology, including atrophy, dilation, and casts (asterisk), in IL-12−/− MRL-Faslpr mice compared with the WT strain (p ≤ 0.001; Fig. 1⇓, b and d). In fact, the IL-12−/− MRL-Faslpr and normal (C3H/Fej, MRL++) tubular pathologies were equivalent. In contrast, the extent of perivascular pathology, consisting of a cuffing of leukocytes around vessels, was not diminished in the IL-12−/− MRL-Faslpr strain compared with the WT strain (Fig. 1⇓, c and e).

FIGURE 1.
FIGURE 1.

IL-12−/− MRL-Faslpr mice are protected from kidney damage during renal disease. a–c, IL-12+/+ and IL-12−/− MRL-Faslpr kidneys (n = 5/group) were assessed for glomerular damage (a), tubular damage (b), and perivascular cell infiltrate (c) at 5 mo of age and compared with age-matched MRL++ (n = 5) and C3H/Fej (n = 5) strains with normal kidneys. Glomerular and tubular, but not perivascular, pathology were reduced in IL-12−/− vs IL-12+/+ MRL-Faslpr mice (∗, p ≤ 0.001). d, Note the severe tubular damage (dilatation and casts; ∗) and glomerular crescents (arrowhead) in IL-12+/+ MRL-Faslpr kidneys. d and e, Hematoxylin and periodic acid-Schiff staining. Magnification: d, ×800; e, ×400. Values are the mean ± SEM.

Reduced leukocytes in the glomeruli and interstitium in IL-12−/− MRL-Faslprkidneys

We compared leukocytes including macrophages (CD68), CD4 and CD8 T cells, and B220 cells in IL-12−/− MRL-Faslpr kidneys at 5 mo of age with age- and sex-matched WT kidneys. There were far fewer macrophages (>50%), CD4 and CD8 T cells, and B220 cells in the IL-12−/−MRL-Faslpr glomeruli and interstitium compared with the WT kidneys (Fig. 2⇓, a and b). The numbers of CD4, CD8, and B220 cells were reduced to normal levels within glomeruli in IL-12−/− MRL-Faslpr kidneys compared with the WT strain. In contrast, the number of macrophages in the glomeruli and interstitium in IL-12−/− MRL-Faslpr mice were not reduced to normal levels (MRL++, C3H/Fej; Fig. 2⇓, a and c). Similarly, the numbers of CD4, CD8, and B220 cells remained above normal in the IL-12−/− MRL-Faslpr interstitium (Fig. 2⇓, b and c). Thus, deleting IL-12 reduces, but does not entirely prevent, intrarenal leukocytic accumulation.

FIGURE 2.
FIGURE 2.

Reduced macrophages and T cells in the glomeruli and interstitium in IL-12−/− MRL-Faslpr kidneys.a and b, Macrophages (CD68), CD4 and CD8 T cells, and B220 cells infiltrated the glomerular and interstitial area in IL-12+/+ MRL-Faslpr kidneys. In contrast, there was a reduction in CD68, CD4, CD8, and B220 cells in IL-12−/− MRL-Faslpr compared with IL-12+/+MRL-Faslpr mice. (∗, p ≤ 0.001; ∗∗, p ≤ 0.01; n = 5/group at 5 mo of age). Note the reduction in macrophages (arrows) and T cells (arrows) illustrated in IL-12−/− MRL-Faslpr kidneys (magnification, ×400). Values are the mean ± SEM.

Diminished Ig and C3 in glomeruli of IL-12−/− MRL-Faslprkidneys

The deposition of IgG and C3 in glomeruli is a characteristic feature of renal disease in MRL-Faslpr mice (33, 34, 35). IL-12+/+ MRL-Faslpr have IgG and C3 deposits within the peripheral glomerular capillary loops and the mesangium at 5 mo of age. We detected a decrease in IgG and C3 in glomeruli (periphery, mesangium) in IL-12−/− MRL-Faslpr mice compared with the WT strain (Fig. 3⇓, a and b, respectively; p ≤ 0.001).

FIGURE 3.
FIGURE 3.

There was less IgG and C3 depositing in renal glomeruli in IL-12−/− MRL-Faslpr kidneys. Intrarenal deposition of IgG (a) and C3 (b) was diminished in IL-12−/− MRL-Faslpr glomeruli compared with IL-12+/+ MRL-Faslprglomeruli at 5 mo of age (n = 5/group; ∗, p ≤ 0.001). Values are the mean ± SEM.

Proteinuria is reduced in IL-12−/− MRL-Faslprmice

Urinary protein levels in IL-12−/− and IL-12+/+ MRL-Faslpr mice, which were undetectable at 2 mo of age, progressively increased from 3–5 mo of age (Fig. 4⇓). By comparison, although urinary protein levels in the IL-12−/− MRL-Faslpr strain rose above normal with advancing age, they remained lower than those in the WT strain. Proteinuria was more accurately evaluated by determining the protein/creatinine ratios from 24-h urine collections. The protein/creatinine ratio was reduced in the IL-12−/− MRL-Faslpr strain compared with the WT strain at 5 mo of age (Fig. 4⇓). However, the urinary protein level in IL-12−/− MRL-Faslpr mice was elevated compared with that in MRL-Faslpr mice with normal kidneys (2 mo of age). Taken together, deleting IL-12 in MRL-Faslpr mice retards, but does not prevent, proteinuria.

FIGURE 4.
FIGURE 4.

Urinary protein was reduced in IL-12−/− MRL-Faslpr mice. Fresh urine samples were evaluated for protein using a spot analysis. IL-12−/− MRL-Faslpr mice (n = 37) had less proteinuria than the IL-12+/+ MRL-Faslpr strain from 3–5 mo of age (n = 47; ∗, p ≤ 0.001). Similarly, the urinary protein/creatinine ratio (milligrams/milligrams) remained suppressed in the IL-12−/− MRL-Faslpr mice compared with the WT strain (∗, p ≤ 0.001, 5 mo of age), but was increased above the normal value (prenephritic MRL-Faslpr mice; ∗, p ≤ 0.001). Values are the mean ± SEM.

Lymphadenopathy, skin lesions, and lung and lacrimal and salivary gland pathology are suppressed in IL-12−/− MRL-Faslprmice

Lymphadenopathy, skin lesions, and splenomegaly are characteristic features of MRL-Faslpr mice (36). Lymphadenopathy progressively increased between 3–5 mo of age in IL-12−/− and IL-12+/+ MRL-Faslpr mice; however, in IL-12−/− mice, the severity was reduced compared with that in WT animals (Fig. 5⇓a). Similarly, skin lesions in the IL-12−/− MRL-Faslpr strain were reduced compared with those in the WT strain (Fig. 5⇓b). Conversely, splenomegaly (as measured by weight) did not differ in IL-12−/− and WT mice at 5 mo of age (0.4 ± 0.0 g (n = 8) and 0.5 ± 0.1 g (n = 6), respectively; p ≥ 0.27).

FIGURE 5.
FIGURE 5.

Gross pathology and histopathology were suppressed in IL-12−/− MRL-Faslpr mice.a, Lymphadenopathy was reduced in IL-12−/− MRL-Faslpr mice (n = 37) compared with IL-12+/+ MRL-Faslpr mice (n = 47; ∗, p ≤ 0.001). b, Skin lesions were 3-fold less in IL-12−/− MRL-Faslpr mice at 4–5 mo of age (n = 47; ∗, p ≤ 0.001). c, Lung pathology in the IL-12−/− MRL-Faslpr strain was reduced (>50%) compared with that in IL-12+/+ MRL-Faslpr mice (n = 11–13; ∗, p ≤ 0.001). d, Lacrimal and salivary gland pathology in the IL-12−/− MRL-Faslpr strain was diminished compared with that in the IL-12+/+ MRL-Faslpr strain (n = 11–13; ∗, p < 0.001; ∗∗, p ≤ 0.005). Values are the mean ± SEM.

Several tissues (lungs, lacrimal and salivary glands), in addition to the kidney, were targeted for autoimmune destruction in the MRL-Faslpr strain. MRL-Faslpr mice developed peribronchiolar and perivascular pathology consisting of leukocytic infiltrates that were predominantly macrophages (6). The lung pathology in the IL-12−/− MRL-Faslpr strain was substantially reduced (>50%) compared with that in the IL-12+/+ MRL-Faslpr strain as evaluated at 5 mo of age (Fig. 5⇑c). Similarly, the MRL-Faslpr mice spontaneously developed inflammation in the lacrimal and salivary (submandibular) glands, resembling Sjögren’s syndrome, a condition that results in dry eyes and mouth (20, 37). Lacrimal and salivary pathology in MRL-Faslpr mice consisted of focal increases in leukocytes. There was a decline in the numbers of leukocytes in lacrimal and salivary glands in the IL-12−/− MRL-Faslpr mice compared with the WT strain (Fig. 5⇑d). These leukocytes were predominantly CD4, with lesser amounts of CD8 and even fewer macrophages and B220 cells (n = 5/group; data not shown). Therefore, MRL-Faslpr mice lacking IL-12 are initially protected from lung, lacrimal gland, and salivary gland pathology.

Survival is extended in IL-12−/− MRL-Faslprmice; renal disease is substantial in moribund IL-12−/− MRL-Faslprmice, while lung and lacrimal and salivary gland pathology and skin lesions remain protected

Survival in IL-12−/−MRL-Faslpr mice was modestly extended compared with that in the WT strain (Fig. 6⇓a, ∗, p ≤ 0.05). To determine whether tissue pathology remained suppressed in IL-12−/− MRL-Faslpr compared with IL-12+/+ MRL-Faslpr moribund mice (n = 10 and n = 5, respectively), we evaluated kidney, lacrimal and salivary gland, lung, and skin pathology (Fig. 6⇓b). Renal pathology in IL-12−/− MRL-Faslpr mice did not remain substantially diminished and became almost as severe as that in the WT strain (p > 0.16). However, the reduction in lung pathology, skin lesions and gland pathology was enduring (Fig. 6⇓b). The decreased skin lesions in the IL-12−/− MRL-Faslpr mice was impressive. Both the incidence and the severity of gross skin lesions in the IL-12−/− MRL-Faslpr mice were minimal compared with those in the WT strain (Fig. 6⇓b). While only a small portion (33%) of the IL-12−/− MRL-Faslpr strain had skin lesions, all of the IL-12+/+MRL-Faslpr strain were afflicted. In addition, the skin lesions evident in IL-12−/− MRL-Faslpr mice were tiny (grade 0.3 ± 0.2) compared with the prominent lesions in the WT strain (grade 2.2 ± 0.5; p ≤ 0.0004). This suggests that eliminating IL-12 in MRL-Faslpr mice retards, but is not sufficient to halt, renal disease. On the other hand, eliminating IL-12 does provide enduring protection from lung and lacrimal and salivary gland pathology and skin lesions in the MRL-Faslpr strain.

FIGURE 6.
FIGURE 6.

Survival was extended in IL-12−/− MRL-Faslpr mice. Lung and lacrimal and salivary gland pathology and skin lesions, but not kidney pathology, were suppressed in IL-12−/− MRL-Faslpr mice. a, The survival rate was modestly extended in IL-12−/− MRL-Faslpr mice compared with that in the WT strain (∗, p ≤ 0.05). b, The lung (∗, p ≤ 0.001), lacrimal gland (∗∗, p ≤ 0.01), and salivary gland (∗∗∗, p ≤ 0.05) pathologies and skin lesions (∗, p pathology 0.001) remained suppressed, whereas renal glomerular and interstitial pathologies were not substantially reduced (p ≥ 0.23 and p ≥ 0.16) in moribund IL-12−/− MRL-Faslpr mice compared with the WT strain.

IFN-γ is decreased in IL-12−/− MRL-Faslprkidneys, while IL-18 remains unchanged

IFN-γ is required for kidney disease in MRL-Faslpr mice (8, 9, 38). To determine whether IFN-γ is reduced in IL-12−/− MRL-Faslpr kidneys, we probed for the expression of IFN-γ transcripts in the renal cortex using real-time PCR. There was a dramatic decrease in IFN-γ transcript expression in IL-12−/− MRL-Faslpr kidneys compared with the WT mice at 5 mo of age (Fig. 7⇓a). However, IFN-γ expression in IL-12−/− MRL-Faslpr kidneys was elevated above normal values (C3H/Fej kidneys).

FIGURE 7.
FIGURE 7.

Decreased intrarenal IFN-γ expression in IL-12−/− MRL-Faslpr mice. a, MRL-Faslpr mice lacking IL-12 had fewer intrarenal IFN-γ transcripts, but similar IL-18 transcripts, compared with the WT strain (∗, p ≤ 0.05). The expressions of IFN-γ and IL-18 were evaluated using real-time PCR. b, Freshly isolated kidney cells stimulated with IL-12 and IL-18 induced less IFN-γ in IL-12−/− MRL-Faslpr kidneys compared with IL-12+/+ MRL-Faslpras measured by ELISA (∗, p ≤ 0.05). c, B220 and CD8 T cells generated less IFN-γ in IL-12−/− MRL-Faslpr mice compared with the WT strain. Values are the mean ± SEM.

To determine whether IFN-γ protein is diminished in the kidney, we evaluated intrarenal IFN-γ at 5 mo of age. IL-18 and IL-12 act synergistically to produce IFN-γ (39). Freshly isolated IL-12−/− MRL-Faslpr kidney cells stimulated with IL-12 and IL-18 (48 h) produced substantially less IFN-γ compared with WT cells, as measured by ELISA (Fig. 7⇑b). Thus, there were fewer IFN-γ-generating cells in IL-12−/− MRL-Faslpr kidneys compared with WT kidneys.

To determine whether IFN-γ increases with advancing renal pathology, we analyzed IL-12−/− and IL-12+/+ MRL-Faslpr moribund mice. We probed the kidneys from these mice for IFN-γ transcripts. Intrarenal IFN-γ transcripts in moribund IL-12−/− MRL-Faslpr were equivalent to those in moribund WT mice (0.82 ± 0.25 and 0.58 ± 0.12, respectively; n = 6/group; p > 0.42). Thus, there was an increase in IFN-γ transcripts with advancing renal disease and death.

IL-12−/− MRL-Faslprkidneys have a reduction in B220 and CD8 IFN-γ-producing cells compared with the WT strain

To determine the cell source of IFN-γ in the kidney, we analyzed IFN-γ in T cells (CD4, CD8, B220), macrophages (CD68), and TEC in freshly isolated cells in the IL-12−/− and IL-12+/+ MRL-Faslpr kidneys. We determined that in IL-12+/+ MRL-Faslpr kidneys, TEC cells produced the most IFN-γ (p ≤ 0.02), while B220-bearing cells and macrophages produced more IFN-γ (p ≤ 0.008) than CD8 T cells, By comparison, CD4 T cells produced the least amount of IFN-γ (p ≤ 0.008; Fig. 7⇑c). We detected a decrease in IFN-γ in the cells bearing the B220 and CD8 markers in IL-12−/− vs IL-12+/+ MRL-Faslpr kidneys (Fig. 7⇑c). We have previously determined that B220-expressing cells in the kidney are the unique T cell population bearing CD4 and CD8 determinants and lacking the B cell determinants, CD21/35 (8). Thus, the reduction in IFN-γ produced by B220 and CD8 T cells appeared to be responsible for the decrease in intrarenal IFN-γ in IL-12−/− MRL-Faslpr mice.

Nephritogenic cytokines (CSF-1, GM-CSF, and IL-4) are reduced in IL-12−/− MRL-Faslprkidneys compared with WT kidneys

CSF-1 (40), GM-CSF (40), and IL-4 (41) are cytokines that promote kidney disease in MRL-Faslpr mice. We determined that these nephritogenic cytokines transcripts were reduced in IL-12−/− MRL-Faslpr kidneys (5 mo of age) compared with WT kidneys (p ≤ 0.01; Fig. 8⇓a). Although there was a decline in TNF-αtranscripts, another nephritogenic cytokine (42), in the IL-12−/− MRL-Faslpr kidneys, this decrease was not significant (p ≥ 0.14; Fig. 8⇓a).

FIGURE 8.
FIGURE 8.

Nephritogenic cytokines were diminished in the IL-12−/− MRL-Faslpr kidneys, while Th1 and Th2 cytokine levels were similar to those in the WT strain. CSF-1, GM-CSF, and IL-4 were decreased in IL-12−/− MRL-Faslpr compared with WT mice at 5 mo of age (∗, p ≤ 0.01). In addition, levels of the Th1 cytokines (IFN-γ (p ≥ 0.06), GM-CSF (p ≥ 0.43), TNF-α (p ≥ 0.19), and the Th2 cytokine, IL-4 (p ≥ 0.26)) remained similar.

IFN-γ, TNF-α, GM-CSF, and IL-4 transcripts remain similar in the IL-12−/− and IL-12+/+ MRL-Faslprlymph nodes

We examined the Th1 cytokines (IFN-γ, TNF-α and GM-CSF) and the Th2 cytokine (IL-4) in the lymph nodes of IL-12−/− MRL-Faslpr and WT mice. We did not detect a difference in Th1 (IFN-γ (p ≥ 0.06), TNF-α (p ≥ 0.19), GM-CSF (p ≥ 0.43), and the Th2 cytokine, IL-4 (p ≥ 0.26), in IL-12−/− and IL-12+/+ MRL-Faslpr lymph nodes at 5 mo of age (Fig. 8⇑b).

Circulating isotypes were not diminished in IL-12−/− MRL-Faslprmice

We determined whether the decrease in Ig deposits in the kidney was related to a decline in circulating Ig isotypes. Although there was a modest reduction in total IgG in IL-12−/− MRL-Faslpr serum, it was not significant (Fig. 9⇓a). We did not detect a difference in IgG1, IgG2a, IgG2b, IgG3, and IgM levels in the circulation of IL-12−/− MRL-Faslpr compared with the WT strain (Fig. 9⇓a). To determine whether there was an alteration in autoantigen-specific serum Ig isotypes, we measured the levels of dsDNA-specific Ig subclasses. We did not detect a difference in the dsDNA-specific IgG isotypes (IgG1, IgG2a, IgG2b, IgG3) in the IL-12−/− and IL-12+/+ MRL-Faslpr serum compared with the WT strain evaluated at five dilutions (1/50 through 1/12,150; Fig. 9⇓b, 1/150 dilution). Taken together, these findings indicate that the decrease in IgG in IL-12−/− MRL-Faslpr glomeruli is not related to a reduction of these Igs or dsDNA-specific Igs in the circulation.

FIGURE 9.
FIGURE 9.

A deficiency in IL-12 did not reduce serum Ig isotypes or Ig isotype levels specific for dsDNA in MRL-Faslpr mice compared with the WT strain. a, Serum from IL-12−/− and IL-12+/+ MRL-Faslpr mice was analyzed for Igs. b, Serum from IL-12−/− and IL-12+/+ MRL-Faslpr mice was analyzed for dsDNA-specific Igs at five dilutions by ELISA at 5 mo of age (n = 5/group). The mean ± SEM for the 1/150 dilution are shown. The dashed line indicates normal mean background levels (C57BL/6 mice, n = 2).

Discussion

MRL-Faslpr mice are an appealing model to identify therapeutic targets, since disease is spontaneous, predictable, and rapid and mimics the multifaceted tissue destruction characteristic of human lupus. We now report that MRL-Faslpr with a genetic deficiency in IL-12 have reduced kidney, lacrimal gland, and salivary gland pathology; diminished lymphadenopathy; and prolonged survival. However, while the protection from lung, skin, and lacrimal and salivary gland pathology was enduring, renal pathology continued to progress, albeit at a slower rate, in the IL-12−/− MRL-Faslpr strain. The decreased severity of renal disease was associated with fewer IFN-γ-expressing cells intrarenally in the IL-12−/− kidneys compared with the WT strain. This may result in part from fewer IFN-γ-generating CD8 and B220 T cells infiltrating the kidney. Furthermore, the diminished renal disease in IL-12−/− MRL-Faslpr mice correlated with a reduction in IgG and C3 deposits in renal glomeruli. Of note, systemic (lymph node) IFN-γ and other Th1 cytokines (GM-CSF, TNF-α) and the Th2 cytokine, IL-4, remained similar in IL-12−/− MRL-Faslpr compared with the WT strain. We suggest that IL-12 alone is a therapeutic target for lung, skin, lacrimal gland, and salivary gland pathology, but renal disease requires the blockade of IL-12 along with other with nephritogenic molecules, such as IFN-γ, to confer long term protection.

It is intriguing that deleting IL-12 has a differential impact on pathology in multiple tissues undergoing autoimmune destruction in MRL-Faslpr mice. While renal injury is transiently delayed, protection from skin, lung, lacrimal gland, and salivary gland disease is more enduring in this strain. The discordant impact on tissue pathology of a single gene deletion in the autoimmune MRL-Faslpr strain is in keeping with prior reports. For example, deleting β2-microglobulin dampens nephritis, but accelerates skin lesions, in MRL-Faslpr mice (43). Furthermore, we have noted an improvement in kidney, lung, lymph node, and skin pathology despite equivalent splenomegaly in the current study as well as in monocyte chemoattractant protein-1-deficient MRL-Faslpr mice (6). The simplest explanation for these tissue differences is the distinctive microenvironment that reflects differing functions. While skin and lungs are barrier sites with specialized immune systems designed to ward off a breach (44, 45, 46), the kidney has other complex functions; it is responsible for homeostasis. In addition, a huge amount of cardiac output (20%) is filtered through the kidney. Thus, it has greater exposure to circulating leukocytes than other tissues and is at increased risk for leukocyte-mediated tissue injury. Future studies are required to detail the elements within the microenvironment that contribute to the relative importance of IL-12 in autoimmune-mediated injury.

There is ample evidence to suggest that IL-12p40 is a pivotal inflammatory mediator in barrier tissues (respiratory tract, skin, and gut). IL-12p40 is produced by macrophages during fibrosis, and IL-12p40-deficient mice are resistant to silica-induced pulmonary inflammation and fibrosis (47). Similarly, airway epithelial cell production of IL-12p40 is a key intermediate for virus-inducible inflammation (48). In the skin, IL-12p40 is enhanced in keratinocytes following UV light exposure and herpes lesions (49, 50, 51). In the gut, blocking IL-12 abrogates mouse experimental colitis (52). Taken together, although we have not determined the precise reason for the enduring protection from skin, lung, and lacrimal and salivary gland pathology in IL-12−/− MRL-Faslpr mice, our data suggest that IL-12 is pivotal in the pathogenesis of these tissues.

Why is kidney disease in MRL-Faslpr mice initially delayed, but eventually progresses in the absence of IL-12? This finding suggests that IL-12 is instrumental in the initiation phase of the disease, but that other nephritogenic molecules contribute to renal disease. Our laboratory and others established that in the absence of IFN-γ or the IFN-γ receptor in MRL-Faslpr mice, kidney disease is prevented (8, 9, 53). Furthermore, we note that renal injury correlates with a reduction in intrarenal IFN-γ. Therefore, it seems plausible that other IFN-γ-generating cytokines along with IL-12 drive lupus nephritis in the MRL-Faslpr strain. IL-18 is one plausible candidate. IL-12 and IL-18 are similar in many ways. 1) IL-12 and IL-18 are up-regulated in the kidney and serum of MRL-Faslpr mice with lupus nephritis and further increase with advancing disease (5, 54). 2) IL-12 and IL-18 induce IFN-γ (28, 55). 3) IL-12 and IL-18 are produced in the kidney by TEC (54, 56). 4) Injecting IL-18 alone or with IL-12 promotes proteinuria and glomerulonephritis (57). However, it is important to note that optimal IFN-γ production requires IL-12 plus IL-18 (58, 59). This is based on the findings that IL-18 plus IL-12 synergistically increase IFN-γ production (60), and mice deficient in IL-18 have suppressed IFN-γ expression despite the presence of IL-12, and vice versa (61). Furthermore, it is possible that IL-18 is a more potent inducer of IFN-γ in the MRL-Faslpr strain than in other mouse strains, since an overexpression of the IL-18R accessory β-chain in this strain has been linked to the lymphocyte hyper-responsiveness and enhanced IFN-γ production (62). In the present study IL-12−/− MRL-Faslpr mice maintain increased levels of intrarenal IL-18, and we identified fewer IFN-γ-producing B220 and CD8 T cells in the IL-12−/− MRL-Faslpr kidney compared with the WT strain. Thus, we suggest that deleting IL-12 retards the rate of accumulating IFN-γ-generating B220 and CD8 T cells within the kidney and, in turn, renal disease. It is possible that as the numbers of intrarenal IFN-γ-generating cells induced by IL-18 and other molecules reaches a critical mass, an amplification loop is triggered, leading to kidney destruction. Of note, the decrease in IFN-γ appears to be restricted to end organs (kidney), since systemic (lymph node) IFN-γ is not altered in MRL-Faslpr mice lacking IL-12. Clearly, the relative contributions of IL-12 and other IFN-γ-generating cytokines in the multiple tissues targeted for destruction in MRL-Faslpr mice require further clarification.

We now report that IFN-γ is largely produced by intrinsic renal cells, TEC, in the MRL-Faslpr kidney, while the relative contributions of leukocytes is B220 and macrophages > CD8 T cells > CD4 T cells. Previous studies in an induced form of glomerulonephritis noted that TEC and CD8 T cells generate IFN-γ; in contrast, macrophages and CD4 T cells did not produce IFN-γ (12). On the other hand, macrophage production of IFN-γ has been linked to glomerulonephritis in MRL-Faslpr mice (63). Thus, the cell types producing IFN-γ and their contributions to nephritis may be dependent on the etiology of renal disease. We note that B220 and CD8 T cells produce diminished levels of intrarenal IFN-γ in IL-12−/− MRL-Faslpr compared with the WT strain. As B220 and CD8 T cells are required for renal disease in MRL-Faslpr mice (7), the generation of IL-12-dependent IFN-γ by these T cells may be instrumental in kidney disease. Additional studies are required to determine the exact contribution of each IFN-γ-producing cell population regulated by IL-12 in lupus nephritis.

If IL-12 promotes renal disease solely by increasing intrarenal IFN-γ, then a more direct therapeutic approach might be to directly target IFN-γ. However, it is not that simple. Unfortunately, eliminating IFN-γ is a double-edged sword. On the one hand, substantial evidence supports the concept that deleting IFN-γ prevents renal disease. Our laboratory and others report that genetic deletion of IFN-γ halts kidney disease and the systemic pathology in MRL-Faslpr mice (8, 9, 53). On the other hand, eliminating IFN-γ can promote renal disease (8, 31, 64, 65). Thus, blocking IL-12 maybe a less risky therapeutic for lupus nephritis than blocking IFN-γ, since there is no evidence that blocking IL-12 promotes nephritis. On the other hand, two strategies designed to block IL-12 in lupus mice have not markedly ameliorated nephritis. Provision of anti-IL-12 Ab in the NZB/W F1 hybrid mouse initiated before the onset of lupus inhibits IgG, anti-dsDNA Ab, but does not prevent nephritis (66). Similarly, IL-12p40 transgenic MRL-Faslpr mice that overexpress IL-12p40, a competitive inhibitor of IL-12, do not have substantial alterations in proteinuria, glomerulonephritis, and survival (67). Nevertheless, since beneficial cytokine blockade is dependent on the treatment initiation stage, the dose, and many other factors, it remains to be determined whether eliminating IL-12 reduces lupus.

The levels of systemic IFN-γ and pathology regulated by IL-12 do not necessary correlate. For example, despite improvement in systemic pathology (lung, lacrimal and salivary glands, skin, and lymphadenopathy), we did not note a reduction in IFN-γ in the lymph nodes of IL-12−/− MRL-Faslpr compared with the WT strain. In addition, there was a reduction in IFN-γ in the serum of IL-12p40 transgenic MRL-Faslpr mice, and yet no improvement in systemic pathology (lymphadenopathy, splenomegaly, glomerulonephritis) (67). While injecting IL-12 accelerates renal disease in MRL-Faslpr mice and increases serum IFN-γ, splenomegaly remains similar to that in control mice (22). Clearly, a more detailed analysis will be required to determine whether there is a central role of IL-12 in IFN-γ production.

We point out that other nephritogenic cytokine (CSF-1, GM-CSF, and IL-4) transcripts are diminished in IL-12−/− MRL-Faslpr kidneys. Thus, it is possible that IL-12 may be responsible for increasing each of these nephritogenic cytokines and, in turn, promoting lupus nephritis. Clearly, additional studies are required to determine the interrelationship of IL-12, IFN-γ, and other nephritogenic cytokines in lupus nephritis.

In conclusion, our data suggest that designing a strategy that blocks IL-12 and perhaps other IFN-γ-dependent pathways may be a therapeutic target to halt the progression of lupus nephritis.

Acknowledgments

We thank Dr. Kevin C. O’Connor for assistance with the dsDNA Ab isotype analysis, Dr. B. S. Vinay Dass for assistance with the ELISA experiments, Dr. Terry K. Means for PCR technical assistance, and Dr. Surya M. Nauli for assistance with the statistical analysis.

Footnotes

  • ↵1 This work was supported by grants from the National Institutes of Health (DK36149 (to V.R.K.), DK56848 (to V.R.K.), DK52369 (to V.R.K.), and 1F32DK6029101 (to D.M.L.)) and the Alliance for Lupus Research (to V.R.K.).

  • ↵2 Address correspondence and reprint requests to Dr. Vicki Rubin Kelley, Harvard Institute of Medicine, 77 avenue Louis Pasteur, Boston, MA 02115. E-mail address: vkelley{at}rics.bwh.harvard.edu

  • 3 Abbreviations used in this paper: DN, double negative; gcs, glomerular cross-sections; TEC, tubular epithelial cell; WT, wild type.

  • Received September 27, 2002.
  • Accepted January 31, 2003.

References

  1. ↵
    Theofilopoulos, A. N., F. J. Dixon. 1981. Etiopathogenesis of murine SLE. Immunol. Rev. 55: 179
    OpenUrlCrossRefPubMed
  2. ↵
    Kelley, V. E., J. B. Roths. 1985. Interaction of mutant lpr gene with background strain influences renal disease. Clin. Immunol. Immunopathol. 37: 220
    OpenUrlCrossRefPubMed
  3. ↵
    Moyer, C. F., J. D. Strandberg, C. L. Reinisch. 1987. Systemic mononuclear-cell vasculitis in MRL/Mp-lpr/lpr mice: a histologic and immunocytochemical analysis. Am. J. Pathol. 127: 229
    OpenUrlPubMed
  4. ↵
    Moore, K. J., T. Wada, S. D. Barbee, V. R. Kelley. 1998. Gene transfer of RANTES elicits autoimmune renal injury in MRL-Faslpr mice. Kidney Int. 53: 1631
    OpenUrlCrossRefPubMed
  5. ↵
    Schwarting, A., G. Tesch, K. Kinoshita, R. Maron, H. L. Weiner, V. R. Kelley. 1999. IL-12 drives IFN-γ-dependent autoimmune kidney disease in MRL-Faslpr mice. J. Immunol. 163: 6884
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Tesch, G. H., S. Maifert, A. Schwarting, B. J. Rollins, V. R. Kelley. 1999. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Faslpr mice. J. Exp. Med. 190: 1813
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Wada, T., T. Naito, R. C. Griffiths, T. M. Coffman, V. R. Kelley. 1997. Systemic autoimmune nephritogenic components induce CSF-1 and TNF-α in MRL kidneys. Kidney Int. 52: 934
    OpenUrlCrossRefPubMed
  8. ↵
    Schwarting, A., T. Wada, K. Kinoshita, G. Tesch, V. R. Kelley. 1998. IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Faslpr mice. J. Immunol. 161: 494
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Haas, C., B. Ryffel, M. Le Hir. 1997. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158: 5484
    OpenUrlAbstract
  10. ↵
    Diaz Gallo, C., A. M. Jevnikar, D. C. Brennan, S. Florquin, A. Pacheco-Silva, V. R. Kelley. 1992. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int. 42: 851
    OpenUrlCrossRefPubMed
  11. ↵
    Manolios, N., L. Schrieber, M. Nelson, C. L. Geczy. 1989. Enhanced interferon-γ (IFN) production by lymph node cells from autoimmune (MRL/1, MRL/n) mice. Clin. Exp. Immunol. 76: 301
    OpenUrlPubMed
  12. ↵
    Timoshanko, J. R., S. R. Holdsworth, A. R. Kitching, P. G. Tipping. 2002. IFN-γ production by intrinsic renal cells and bone marrow-derived cells is required for full expression of crescentic glomerulonephritis in mice. J. Immunol. 168: 4135
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Hsieh, C. S., S. E. Macatonia, C. S. Tripp, S. F. Wolf, A. O’Garra, K. M. Murphy. 1993. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547
    OpenUrlAbstract/FREE Full Text
  14. ↵
    D’Andrea, A., M. Rengaraju, N. M. Valiante, J. Chehimi, M. Kubin, M. Aste, S. H. Chan, M. Kobayashi, D. Young, E. Nickbarg, et al 1992. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J. Exp. Med. 176: 1387
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Trinchieri, G.. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14: 335
    OpenUrlCrossRefPubMed
  16. ↵
    Gately, M. K., B. B. Desai, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, F. J. Podlaski, P. C. Familletti, F. Sinigaglia, R. Chizonnite, U. Gubler, et al 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147: 874
    OpenUrlAbstract
  17. ↵
    Perussia, B., S. H. Chan, A. D’Andrea, K. Tsuji, D. Santoli, M. Pospisil, D. Young, S. F. Wolf, G. Trinchieri. 1992. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes, and NK cells. J. Immunol. 149: 3495
    OpenUrlAbstract
  18. ↵
    Chan, S. H., B. Perussia, J. W. Gupta, M. Kobayashi, M. Pospisil, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, G. Trinchieri. 1991. Induction of interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173: 869
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Takahashi, S., L. Fossati, M. Iwamoto, R. Merino, R. Motta, T. Kobayakawa, S. Izui. 1996. Imbalance towards Th1 predominance is associated with acceleration of lupus-like autoimmune syndrome in MRL mice. J. Clin. Invest. 97: 1597
    OpenUrlCrossRefPubMed
  20. ↵
    Mustafa, W., J. Zhu, G. Deng, A. Diab, H. Link, L. Frithiof, B. Klinge. 1998. Augmented levels of macrophage and Th1 cell-related cytokine mRNA in submandibular glands of MRL/lpr mice with autoimmune sialoadenitis. Clin. Exp. Immunol. 112: 389
    OpenUrlCrossRefPubMed
  21. ↵
    Seder, R. A., R. Gazzinelli, A. Sher, W. E. Paul. 1993. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA 90: 10188
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Huang, F. P., G. J. Feng, G. Lindop, D. I. Stott, F. Y. Liew. 1996. The role of interleukin 12 and nitric oxide in the development of spontaneous autoimmune disease in MRL?MP-lpr?lpr mice. J. Exp. Med. 183: 1447
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827
    OpenUrlAbstract/FREE Full Text
  24. ↵
    Stern, A. S., F. J. Podlaski, J. D. Hulmes, Y. C. Pan, P. M. Quinn, A. G. Wolitzky, P. C. Familletti, D. L. Stremlo, T. Truitt, R. Chizzonite, et al 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87: 6808
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Schoenhaut, D. S., A. O. Chua, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, W. McComas, P. C. Familletti, M. K. Gately, U. Gubler. 1992. Cloning and expression of murine IL-12. J. Immunol. 148: 3433
    OpenUrlAbstract
  26. ↵
    Wolf, S. F., P. A. Temple, M. Kobayashi, D. Young, M. Dicig, L. Lowe, R. Dzialo, L. Fitz, C. Ferenz, R. M. Hewick, et al 1991. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol. 146: 3074
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Gubler, U., A. O. Chua, D. S. Schoenhaut, C. M. Dwyer, W. McComas, R. Motyka, N. Nabavi, A. G. Wolitzky, P. M. Quinn, P. C. Familletti, et al 1991. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc. Natl. Acad. Sci. USA 88: 4143
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Magram, J., S. E. Connaughton, R. R. Warrier, D. M. Carvajal, C. Y. Wu, J. Ferrante, C. Stewart, U. Sarmiento, D. A. Faherty, M. K. Gately. 1996. IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 4: 471
    OpenUrlCrossRefPubMed
  29. ↵
    Jankovic, D., M. C. Kullberg, S. Hieny, P. Caspar, C. M. Collazo, A. Sher. 2002. In the absence of IL-12, CD4+ T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10−/− setting. Immunity 16: 429
    OpenUrlCrossRefPubMed
  30. ↵
    Moore, K. J., T. Naito, C. Martin, V. R. Kelley. 1996. Enhanced response of macrophages to CSF-1 in autoimmune mice: a gene transfer strategy. J. Immunol. 157: 433
    OpenUrlAbstract
  31. ↵
    Schwarting, A., K. Moore, T. Wada, G. Tesch, H. J. Yoon, V. R. Kelley. 1998. IFN-γ limits macrophage expansion in MRL-Faslpr autoimmune interstitial nephritis: a negative regulatory pathway. J. Immunol. 160: 4074
    OpenUrlAbstract/FREE Full Text
  32. ↵
    O’Connor, K. C., K. Nguyen, B. D. Stollar. 2001. Recognition of DNA by VH and Fv domains of an IgG anti-poly(dC) antibody with a singly mutated VH domain. J. Mol. Recognit. 14: 18
    OpenUrlCrossRefPubMed
  33. ↵
    Santoro, T. J., J. P. Portanova, B. L. Kotzin. 1988. The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J. Exp. Med. 167: 1713
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Sobel, E. S., T. Katagiri, K. Katagiri, S. C. Morris, P. L. Cohen, R. A. Eisenberg. 1991. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J. Exp. Med. 173: 1441
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Merino, R., M. Iwamoto, L. Fossati, S. Izui. 1993. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB × NZW)F1 and MRL/MpJ-lpr/lpr mice. J. Immunol. 151: 6509
    OpenUrlAbstract
  36. ↵
    Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148: 1198
    OpenUrlAbstract/FREE Full Text
  37. ↵
    Hoffman, R. W., M. A. Alspaugh, K. S. Waggie, J. B. Durham, S. E. Walker. 1984. Sjogren’s syndrome in MRL/l and MRL/n mice. Arthritis Rheum. 27: 157
    OpenUrlCrossRefPubMed
  38. ↵
    Lawson, B. R., G. J. Prud’homme, Y. Chang, H. A. Gardner, J. Kuan, D. H. Kono, A. N. Theofilopoulos. 2000. Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J. Clin. Invest. 106: 207
    OpenUrlCrossRefPubMed
  39. ↵
    Yoshimoto, T., K. Takeda, T. Tanaka, K. Ohkusu, S. Kashiwamura, H. Okamura, S. Akira, K. Nakanishi. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-γ production. J. Immunol. 161: 3400
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Naito, T., H. Yokoyama, K. J. Moore, G. Dranoff, R. C. Mulligan, V. R. Kelley. 1996. Macrophage growth factors introduced into the kidney initiate renal injury. Mol. Med. 2: 297
    OpenUrlPubMed
  41. ↵
    Peng, S. L., J. Moslehi, J. Craft. 1997. Roles of interferon-γ and interleukin-4 in murine lupus. J. Clin. Invest. 99: 1936
    OpenUrlCrossRefPubMed
  42. ↵
    Moore, K. J., K. Yeh, T. Naito, V. R. Kelley. 1996. TNF-α enhances colony-stimulating factor-1-induced macrophage accumulation in autoimmune renal disease. J. Immunol. 157: 427
    OpenUrlAbstract
  43. ↵
    Chan, O. T., V. Paliwal, J. M. McNiff, S. H. Park, A. Bendelac, M. J. Shlomchik. 2001. Deficiency in β2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Faslpr mice: an example of disease regulation at the organ level. J. Immunol. 167: 2985
    OpenUrlAbstract/FREE Full Text
  44. ↵
    Bos, J. D.. 1997. The skin as an organ of immunity. Clin. Exp. Immunol. 107: (Suppl. 1):3
    OpenUrlPubMed
  45. ↵
    Laissue, J. A., B. B. Chappuis, C. Muller, J. C. Reubi, J. O. Gebbers. 1993. The intestinal immune system and its relation to disease. Dig. Dis. 11: 298
    OpenUrlCrossRefPubMed
  46. ↵
    Semenzato, G., M. Bortolin, M. Facco, C. Tassinari, R. Sancetta, C. Agostini. 1996. Lung lymphocytes: origin, biological functions, and laboratory techniques for their study in immune-mediated pulmonary disorders. Crit. Rev. Clin. Lab. Sci. 33: 423
    OpenUrlCrossRefPubMed
  47. ↵
    Huaux, F., M. Arras, D. Tomasi, V. Barbarin, M. Delos, J. P. Coutelier, A. Vink, S. H. Phan, J. C. Renauld, D. Lison. 2002. A profibrotic function of IL-12p40 in experimental pulmonary fibrosis. J. Immunol. 169: 2653
    OpenUrlAbstract/FREE Full Text
  48. ↵
    Walter, M. J., N. Kajiwara, P. Karanja, M. Castro, M. J. Holtzman. 2001. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J. Exp. Med. 193: 339
    OpenUrlAbstract/FREE Full Text
  49. ↵
    Aragane, Y., H. Riemann, R. S. Bhardwaj, A. Schwarz, Y. Sawada, H. Yamada, T. A. Luger, M. Kubin, G. Trinchieri, T. Schwarz. 1994. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J. Immunol. 153: 5366
    OpenUrlAbstract
  50. ↵
    Kondo, S., K. Jimbow. 1998. Dose-dependent induction of IL-12 but not IL-10 from human keratinocytes after exposure to ultraviolet light A. J. Cell Physiol. 177: 493
    OpenUrlCrossRefPubMed
  51. ↵
    Mikloska, Z., A. M. Kesson, M. E. Penfold, A. L. Cunningham. 1996. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-γ. J. Infect. Dis. 173: 7
    OpenUrlAbstract/FREE Full Text
  52. ↵
    Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stuber, W. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281
    OpenUrlAbstract/FREE Full Text
  53. ↵
    Balomenos, D., R. Rumold, A. N. Theofilopoulos. 1998. Interferon-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101: 364
    OpenUrlCrossRefPubMed
  54. ↵
    Fan, X., B. Oertli, R. P. Wuthrich. 1997. Up-regulation of tubular epithelial interleukin-12 in autoimmune MRL-Faslpr mice with renal injury. Kidney Int. 51: 79
    OpenUrlCrossRefPubMed
  55. ↵
    Okamura, H., H. Tsutsi, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378: 88
    OpenUrlCrossRefPubMed
  56. ↵
    Faust, J., J. Menke, J. Kriegsmann, V. R. Kelley, W. J. Mayet, P. R. Galle, A. Schwarting. 2002. Correlation of renal tubular epithelial cell-derived interleukin-18 up-regulation with disease activity in MRL-Faslpr mice with autoimmune lupus nephritis. Arthritis Rheum. 46: 3083
    OpenUrlCrossRefPubMed
  57. ↵
    Esfandiari, E., I. B. McInnes, G. Lindop, F. P. Huang, M. Field, M. Komai-Koma, X. Wei, F. Y. Liew. 2001. A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. J. Immunol. 167: 5338
    OpenUrlAbstract/FREE Full Text
  58. ↵
    Robinson, D., K. Shibuya, A. Mui, F. Zonin, E. Murphy, T. Sana, S. B. Hartley, S. Menon, R. Kastelein, F. Bazan, et al 1997. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 7: 571
    OpenUrlCrossRefPubMed
  59. ↵
    Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, M. Kurimoto. 1997. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158: 1541
    OpenUrlAbstract
  60. ↵
    Nakamura, S., T. Otani, Y. Ijiri, R. Motoda, M. Kurimoto, K. Orita. 2000. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 164: 3330
    OpenUrlAbstract/FREE Full Text
  61. ↵
    Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8: 383
    OpenUrlCrossRefPubMed
  62. ↵
    Neumann, D., E. Del Giudice, A. Ciaramella, D. Boraschi, P. Bossu. 2001. Lymphocytes from autoimmune MRLlpr/lpr mice are hyperresponsive to IL-18 and overexpress the IL-18 receptor accessory chain. J. Immunol. 166: 3757
    OpenUrlAbstract/FREE Full Text
  63. ↵
    Carvalho-Pinto, C. E., M. I. Garcia, M. Mellado, J. M. Rodriguez-Frade, J. Martin-Caballero, J. Flores, A. C. Martinez, D. Balomenos. 2002. Autocrine production of IFN-γ by macrophages controls their recruitment to kidney and the development of glomerulonephritis in MRL/lpr mice. J. Immunol. 169: 1058
    OpenUrlAbstract/FREE Full Text
  64. ↵
    Ring, G. H., Z. Dai, S. Saleem, F. K. Baddoura, F. G. Lakkis. 1999. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-γ-deficient mice. J. Immunol. 163: 2243
    OpenUrlAbstract/FREE Full Text
  65. ↵
    Diaz-Gallo, C., V. R. Kelley. 1993. Self-regulation of autoreactive kidney-infiltrating T cells in MRL-lpr nephritis. Kidney Int. 44: 692
    OpenUrlCrossRefPubMed
  66. ↵
    Nakajima, A., S. Hirose, H. Yagita, K. Okumura. 1997. Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J. Immunol. 158: 1466
    OpenUrlAbstract
  67. ↵
    Yasuda, T., T. Yoshimoto, A. Tsubura, A. Matsuzawa. 2001. Clear suppression of Th1 responses but marginal amelioration of autoimmune manifestations by IL-12p40 transgene in MRL-FASlprcg/FASlprcg mice. Cell Immunol. 210: 77
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section